STOCK TITAN
  1. Home
  2. News
  3. CNTG

Centogene N.V. Common Shares - CNTG STOCK NEWS

Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.

Centogene N.V. (symbol: CNTG) is a leading global company in the field of genetic diagnostic testing for rare hereditary diseases. With an expansive test portfolio covering over 2,800 genes, as well as biochemical and biomarker tests, the company offers unparalleled expertise in whole exome sequencing and whole genome sequencing. Centogene's mission is to provide data-driven, life-changing answers to patients, physicians, and pharmaceutical companies by diagnosing the root causes of symptoms early on.

Centogene leverages its unique CentoMD® mutation database, integrating genetic and clinical information to deliver the highest quality genetic testing and biomarker development. This extensive database allows the company to maintain the largest systematic documentation of genetic results worldwide.

Beyond individual diagnostic services, Centogene is a pivotal partner for pharmaceutical companies, offering essential services such as early patient recruitment, epidemiological insights, biomarker discovery, and patient monitoring. The company operates in two main segments: pharmaceutical and diagnostics, serving regions including Europe, the Middle East, North America, and Latin America.

Recent achievements include the launch of innovative genomic and multiomic products, a significant joint venture in Saudi Arabia, and expanded collaborations with long-standing and new pharma partners. Despite the challenges posed by current financial markets, Centogene remains committed to growth and profitability, exploring strategic alternatives to unlock value for its stakeholders.

With ISO, CAP, and CLIA certified multiomic reference laboratories in Germany, Centogene's research and development efforts have led to over 285 peer-reviewed publications. The company's pioneering work in rare and neurodegenerative diseases has fostered collaborations with over 50 pharmaceutical partners, accelerating drug discovery and development.

To discover more about Centogene's products, pipeline, and patient-driven purpose, visit their website and follow them on LinkedIn.

News

CENTOGENE Announces Voting Results of Extraordinary General Meeting

Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) announced the voting results of the Company’s Extraordinary General Meeting, including the adoption of Dutch statutory annual accounts for the financial year ended December 31, 2022, all passed by the requisite majority.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
none
-
News

CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) has achieved its initial recruitment and genetic testing milestone in the EFRONT Study, aimed at advancing the genetic understanding of frontotemporal dementia (FTD). The study is conducted with support from Alector, a clinical-stage biotechnology company. CENTOGENE will continue to work with its network of physicians to enroll patients in the study under its Cento-FTD Program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
-
News

CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction

Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) has formed a new joint venture (JV) with Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF), to provide state-of-the-art genomic and multiomic testing services to patients, health systems, biopharma clients, and research institutions across the Gulf Cooperation Council (GCC) region. The JV, Lifera Omics, located in Riyadh, Saudi Arabia, will receive an additional $10 million upfront JV milestone payment, following an initial $30 million investment from Lifera. CENTOGENE will have an 80% ownership structure in Lifera Omics and will be eligible for performance-related milestone payments and revenue-based royalties until the year 2033.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
none
News

CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism

Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) announced the discovery of a new form of early-onset dystonia and parkinsonism related to the ACBD6 gene. The landmark study published in Brain journal reveals that bi-allelic pathogenic variants in the ACBD6 gene lead to a distinct neurodevelopmental syndrome with complex cognitive and movement disorders. The study identified 45 patients from 29 families across the globe and aims to guide further research for potential treatments and to understand genetic causes and pathways leading to Parkinson’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.39%
Tags
none
-
News

CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering

Rhea-AI Summary
Centogene expands MOx diagnostic portfolio with RNA sequencing for better disease understanding
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none
-
News

CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
Centogene N.V. CEO to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
conferences
News

CENTOGENE Reports First Half 2023 Financial Results

Rhea-AI Summary
Centogene N.V. reports strong revenues and steady growth in both diagnostics and pharma segments. Total revenues for H1 2023 increased by 15.1% to €24.6 million. Diagnostics segment revenues increased by 12.7% to €16.3 million, driven by an increase in test requests. Pharma segment revenues increased by 20.3% to €8.3 million. Operating loss decreased to €21.3 million. Total segment adjusted EBITDA decreased by 45.3% to €2.9 million. Cash and cash equivalents were €14.2 million as of June 30, 2023. Strategic collaboration with Lifera secures $30 million investment and approx. $50 million in upfront payment and milestones. Positive financial performance reaffirms full year 2023 revenue growth guidance of 10% to 15%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
earnings
-
News

CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients

Rhea-AI Summary
Results confirm lyso-Gb1 as a sensitive biomarker for Gaucher disease, predicting clinical course and improving personalized care. Significant correlation found between lyso-Gb1 levels and disease severity. Study sets standard for Gaucher disease care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.04%
Tags
none
-
News

CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Rhea-AI Summary
Centogene N.V. receives notification from Nasdaq regarding non-compliance with minimum Market Value of Publicly Held Shares requirement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.04%
Tags
none
News

CENTOGENE to Participate in Upcoming Conferences in August

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
conferences

FAQ

What is the current stock price of Centogene N.V. Common Shares (CNTG)?

The current stock price of Centogene N.V. Common Shares (CNTG) is $0.5194 as of August 8, 2024.

What is the market cap of Centogene N.V. Common Shares (CNTG)?

The market cap of Centogene N.V. Common Shares (CNTG) is approximately 9.4M.

What does Centogene N.V. specialize in?

Centogene N.V. specializes in genetic diagnostic testing for rare hereditary diseases and offers a broad portfolio of genetic, biochemical, and biomarker tests.

What is CentoMD®?

CentoMD® is Centogene's mutation database that integrates genetic and clinical information, enabling high-quality genetic testing and biomarker development.

Which segments does Centogene operate in?

Centogene operates in two segments: pharmaceutical and diagnostics.

What regions does Centogene serve?

Centogene serves Europe, the Middle East, North America, and Latin America.

Who are Centogene’s main partners?

Centogene partners with leading pharmaceutical companies for services such as patient recruitment, biomarker discovery, and patient monitoring.

What are some recent achievements of Centogene?

Recent achievements include launching innovative genomic products, forming a joint venture in Saudi Arabia, and expanding pharma collaborations.

How does Centogene contribute to drug discovery?

Centogene accelerates drug discovery through partnerships with pharmaceutical companies, leveraging their extensive genetic data and multiomic technologies.

What research certifications does Centogene hold?

Centogene holds ISO, CAP, and CLIA certifications for their multiomic reference laboratories in Germany.

How extensive is Centogene's physician network?

Centogene has built a network of approximately 30,000 active physicians since its founding in 2006.

Where can I learn more about Centogene?

You can learn more about Centogene by visiting their website at www.centogene.com and following them on LinkedIn.

Stock CNTG logo
Centogene N.V. Common Shares

Nasdaq:CNTG

CNTG Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CNTG Stock Data

9.43M
29.00M
4.57%
66.89%
0.28%
Diagnostics & Research
Healthcare
Link
United States of America
Rostock